CJC-1295 (no DAC) vs Tesamorelin
Truncated GHRH(1-29) against full-length GHRH(1-44). Sequence length is the whole distinction and it is routinely glossed over.
Growth Hormone
CJC-1295 (no DAC)
Modified GRF (1-29) analog with four amino acid substitutions conferring resistance to enzymatic degradation.
Growth Hormone
Tesamorelin
Stabilized 44-amino-acid GHRH analog — the longest GHRH sequence in common research use.
Side by side
| Dimension | CJC-1295 (no DAC) | Tesamorelin |
|---|---|---|
| Molecular weight | 3367.9 g/mol | 5135.86 g/mol |
| Size class | mid-length peptide | long peptide |
| CAS number | 863288-34-0 | 218949-48-5 |
| Research area | growth hormone | growth hormone |
| Sequence | Not published as a linear sequence | Not published as a linear sequence |
| Available sizes | 5mg, 10mg | 10mg, 15mg |
| Entry price | $39 | $64 |
| Cost per mg | $5.80 | $5.93 |
Mechanism
CJC-1295 (no DAC)
CJC-1295 without DAC — more precisely Modified GRF (1-29) — is a 29-amino-acid GHRH analog carrying four substitutions (D-Ala2, Gln8, Ala15, Leu27) that increase stability against DPP-4 cleavage and plasma degradation. The 'no DAC' designation distinguishes it from the drug affinity complex variant, which incorporates a maleimido group for albumin conjugation and a substantially longer half-life. The two are frequently conflated in supplier catalogs; they are pharmacokinetically very different molecules.
Tesamorelin
Tesamorelin is a synthetic analog of full-length human GHRH(1-44) with a trans-3-hexenoyl group attached at the N-terminus, conferring resistance to DPP-4 cleavage. It is distinguished from sermorelin and Modified GRF (1-29) by sequence length: those are truncated to the first 29 residues, whereas tesamorelin retains the complete 44-residue sequence. It has an established clinical literature, which is uncommon in this catalog.
Evidence quality
Mechanism is not the same as evidence. Where we have assessed the literature, the verdict is stated plainly.
CJC-1295 (no DAC)
Evidence base: the GHRH receptor pathway is well established. Compound-specific evidence for the no-DAC form is limited, and the most-cited pharmacokinetic result belongs to the DAC version, which is a different molecule.
Full research reference →Tesamorelin
Evidence base: strong for the approved indication, supported by pooled phase 3 data with safety extension. Evidence outside that population and endpoint is limited, and the recent neurocognitive work is single-study.
Full research reference →Research applications
CJC-1295 (no DAC)
- GHRH receptor binding and activation studies
- Comparative half-life studies against DAC-conjugated variants
- Combination studies with GHS-R1a agonists
- Enzymatic stability and degradation kinetics
Tesamorelin
- GHRH receptor binding and activation studies
- Comparative studies against truncated GHRH analogs
- Visceral adipose tissue metabolism research
- IGF-1 axis response profiling
Common questions
What is the difference between CJC-1295 (no DAC) and Tesamorelin?
CJC-1295 (no DAC) is modified GRF (1-29) analog with four amino acid substitutions conferring resistance to enzymatic degradation. Tesamorelin is stabilized 44-amino-acid GHRH analog — the longest GHRH sequence in common research use. They differ in molecular weight (3367.9 vs 5135.86 g/mol) and in the pathways they are studied against.
Which is more cost-effective per milligram, CJC-1295 (no DAC) or Tesamorelin?
CJC-1295 (no DAC) is lower at approximately $5.80 per milligram at its best tier, against $5.93 for the other. Cost per milligram is only meaningful relative to the concentrations a given protocol requires, since these compounds are not used at comparable masses.
Can CJC-1295 (no DAC) and Tesamorelin be studied together?
Combination designs appear in the published literature for a number of these compounds. Whether it is appropriate for a given protocol depends entirely on the model and endpoint. We supply research compounds and do not provide protocol guidance — consult the primary literature for your specific model.
How should CJC-1295 (no DAC) and Tesamorelin be stored?
Store lyophilized powder at -20°C protected from light. Reconstituted solution stable at 2-8°C for up to 30 days. For Tesamorelin: Store lyophilized at -20°C protected from light. Reconstituted at 2-8°C for up to 30 days.
Which has the stronger evidence base?
CJC-1295 (no DAC) — Evidence base: the GHRH receptor pathway is well established. Compound-specific evidence for the no-DAC form is limited, and the most-cited pharmacokinetic result belongs to the DAC version, which is a different molecule. Tesamorelin — Evidence base: strong for the approved indication, supported by pooled phase 3 data with safety extension. Evidence outside that population and endpoint is limited, and the recent neurocognitive work is single-study.
All products sold on this website are intended for research and identification purposes only. These products are not intended for human dosing, injection, or ingestion.
Comparison generated from Lyra Vital catalog data. Every specification is reconciled against the certificate of analysis for the shipped batch.